DOI QR코드

DOI QR Code

Immunotherapeutic Effects of Dendritic Cells Pulsed with a Coden-optimized HPV 16 E6 and E7 Fusion Gene in Vivo and in Vitro

  • Zhou, Zhi-Xiang (College of Life Science and Bioengineering, Beijing University of Technology) ;
  • Li, Dan (College of Life Science and Bioengineering, Beijing University of Technology) ;
  • Guan, Shan-Shan (College of Life Science and Bioengineering, Beijing University of Technology) ;
  • Zhao, Chen (College of Life Science and Bioengineering, Beijing University of Technology) ;
  • Li, Ze-Lin (College of Life Science and Bioengineering, Beijing University of Technology) ;
  • Zeng, Yi (College of Life Science and Bioengineering, Beijing University of Technology)
  • Published : 2015.05.18

Abstract

Background: Cervical cancer is the second most common cause of cancer related death of women. Persistent HPV infection, especially with high-risk types such as HPV16 and HPV18, has been identified to be the primary cause of cervical cancer. E6 and E7 are the major oncoproteins of high-risk HPVs, which are expressed exclusively in HPV infected tissues, and thereby represent ideal therapeutic targets for immunotherapy of cervical cancer. Materials and Methods: In this work, we used recombinant adenovirus expressing coden-optimized HPV16 E6 and E7 fusion protein (Ad-ofE6E7) to prime dendritic cells (DC-ofE6E7), to investigate the ability of primed DC vaccine in eliciting antitumor immunity in vitro and vivo. Results: Our results indicated that DC-ofE6E7 vaccine co-culturing with splenocytes could strongly induce a tumor-specific cytotoxic T lymphocyte (CTL) response and kill the TC-1 cells effectively in vitro. Moreover, DC-ofE6E7 vaccine induced protective immunity against the challenge of TC-1 cancer cells in vivo. Conclusions: The results suggested that the HPV16 ofE6E7 primed DC vaccine has potential application for cervical cancer immunotherapy.

Keywords

Human papillomavirus 16;E6;E7;dendritic cells;vaccine;cervical cancer

References

  1. Aggarwal P (2014). Cervical cancer: can it be prevented? World J Clin Oncol, 5, 775-80. https://doi.org/10.5306/wjco.v5.i4.775
  2. Bellone S, Pecorelli S, Cannon MJ, et al (2007). Advances in dendritic cell-based therapeutic vaccines for cervical cancer. Expert Rev Anticancer Ther, 7, 1473-86. https://doi.org/10.1586/14737140.7.10.1473
  3. Chansaenroj J, Theamboonlers A, et al (2012). Whole genome analysis of human papillomavirus type 16 multiple infection in cervical cancer patients. Asian Pac J Cancer Prev, 13, 599-606. https://doi.org/10.7314/APJCP.2012.13.2.599
  4. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  5. Jiang P, Yue Y (2014). Human papillomavirus oncoproteins and apoptosis (Review). Exp Ther Med, 7, 3-7.
  6. Kozlowska A, Mackiewicz J, Mackiewicz A (2013). Therapeutic gene modified cell based cancer vaccines. Gene, 525, 200-7. https://doi.org/10.1016/j.gene.2013.03.056
  7. Lutz MB, Kukutsch N, Ogilvie ALJ, et al (1999). An advanced culture method for generating large quantities of highly pure Dendritic cells from mouse Bone Marrow. J Immunol Methods, 223, 77-92. https://doi.org/10.1016/S0022-1759(98)00204-X
  8. Meixlsperger S, Leung CS, Ramer PC, et al (2013). CD141+ dendritic cells produce prominent amounts of IFN-${\alpha}$ after dsRNA recognition and can be targeted via DEC-205 in humanized mice. Blood, 121, 5034-44. https://doi.org/10.1182/blood-2012-12-473413
  9. Mellman I, Steinman RM (2001). Dendritic cells: specialized and regulated antigen processing machines. Cell, 106, 255-8. https://doi.org/10.1016/S0092-8674(01)00449-4
  10. Nakagawa S, Wantanabe S, Yoshikawa H, et al (1995). Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of P53 in vitro. Virology, 212, 535-42. https://doi.org/10.1006/viro.1995.1511
  11. Ohlschlager P, Quetting M, Alvarez G, et al (2009). Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequenceoptimized genetic adjuvants. Int J Cancer, 125, 189-98. https://doi.org/10.1002/ijc.24333
  12. Palucka K, and Banchereau J (2012). Cancer immunotherapy via dendritic cells. Nat Rev Cancer, 12, 265-77. https://doi.org/10.1038/nrc3258
  13. Ramanathan P, Ganeshrajah S, Raghanvan R (2014). Development and clinical evaluation of dendritic cell vaccines for HPV related cervical cancer-a feasibility study. Asian Pac J Cancer Prev, 15, 5909-16. https://doi.org/10.7314/APJCP.2014.15.14.5909
  14. Schlitzer A, McGovern N, Teo P, et al (2013). IRF4 Transcription factor-dependent CD11b (+) Dendritic cells in Human and mouse control Mucosal IL-17 Cytokine responses. Immunity, 38, 970-83. https://doi.org/10.1016/j.immuni.2013.04.011
  15. Seo SH, Jin HT, Park SH, et al (2009). Optimal induction of Hpv DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. Vaccine, 27, 5906-12. https://doi.org/10.1016/j.vaccine.2009.07.033
  16. Tanchot C, Terme M, Pere H, Tran, T, et al (2013). Tumorinfiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance. Cancer Microenviron, 6, 147-57. https://doi.org/10.1007/s12307-012-0122-y
  17. Tran N, Hung C, Roden R, Wu T (2014). Control of HPV infection and related cancer through vaccination. Recent Results Cancer Res, 193, 149-71. https://doi.org/10.1007/978-3-642-38965-8_9
  18. Wu X, Liu X, Jiao Q (2014). Cytotoxic T Lymphocytes elicited by dendritic cell-targeted delivery of human papillomavirus type-16 E6/E7 fusion gene exert lethal effects on CaSki cells. Asian Pac J Cancer Prev, 15, 2447-51. https://doi.org/10.7314/APJCP.2014.15.6.2447
  19. Xie Q, Zhou Z, Li Z, Zeng Y (2011). Transforming activity of a novel mutant of HPV16 E6E7 fusion gene. Virol Sin, 26, 206-13 https://doi.org/10.1007/s12250-011-3178-9
  20. Yan J, Reichenbach DK, Corbitt N, et al (2009). Induction of antitumor immunity in vivo following delivery of a novel Hpv-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine, 27, 431-40. https://doi.org/10.1016/j.vaccine.2008.10.078
  21. Zhou Z, Zhao C, Li Q, Zeng Y (2014). A novel mutant of Human Papillomavirus Type 18 E6E7 fusion gene and its transforming activity. Asian Pac J Cancer Prev, 15, 7395-9. https://doi.org/10.7314/APJCP.2014.15.17.7395

Cited by

  1. Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases vol.12, pp.6, 2016, https://doi.org/10.1080/21645515.2015.1136039
  2. Targeting Persistent Human Papillomavirus Infection vol.9, pp.8, 2017, https://doi.org/10.3390/v9080229
  3. Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus vol.9, pp.1664-3224, 2018, https://doi.org/10.3389/fimmu.2018.02478